Sawyer T K
ARIAD Pharmaceuticals, Inc., Cambridge, MA 02139, USA.
Biopolymers. 1998;47(3):243-61. doi: 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P.
Src homology-2 (SH2) domains and their associated catalytic or noncatalytic proteins constitute critical signal transduction targets for drug discovery. Such SH2 proteins are found in the regulation of a number of cellular processes, including growth, mitogenesis, motility, metabolism, immune response, and gene transcription. From the relationship of tyrosine phosphorylation and intracellular regulation by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), the dynamic and reversible binding interactions of SH2 domain containing proteins with their cognate phosphotyrosine (pTyr) containing proteins provide a third dimensionality to the orchestration of signal transduction pathways that exist as a result of pTyr formation, degradation, and molecular recognition events. This review highlights several key research achievements impacting our current understanding of SH2 structure, mechanisms, and drug discovery that underlie the role(s) of SH2 domains in signal transduction processes, cellular functions, and disease states.
Src同源结构域2(SH2)及其相关的催化或非催化蛋白构成了药物研发的关键信号转导靶点。此类SH2蛋白存在于许多细胞过程的调控中,包括生长、有丝分裂、运动、代谢、免疫反应和基因转录。从蛋白酪氨酸激酶(PTK)和蛋白酪氨酸磷酸酶(PTP)介导的酪氨酸磷酸化与细胞内调控的关系来看,含SH2结构域的蛋白与其含同源磷酸酪氨酸(pTyr)的蛋白之间动态且可逆的结合相互作用,为因pTyr形成、降解和分子识别事件而存在的信号转导通路的协调提供了第三个维度。本综述重点介绍了几项关键研究成果,这些成果影响了我们目前对SH2结构、机制和药物研发的理解,而这些理解构成了SH2结构域在信号转导过程、细胞功能和疾病状态中所起作用的基础。